Biocon Limited (IN:BIOCON)
:BIOCON
BIOCON Stock Chart & Stats
₹364.20
₹0.80(0.22%)
At close: 4:00 PM EST
₹364.20
₹0.80(0.22%)
Day’s Range― - ―
52-Week Range₹303.85 - ₹424.95
Previous CloseN/A
Volume1.20M
Average Volume (3M)208.50K
Market Cap
₹566.77B
Enterprise Value₹598.28B
Total Cash (Recent Filing)₹64.69B
Total Debt (Recent Filing)₹165.35B
Price to Earnings (P/E)91.6
Beta1.12
Next Earnings
May 14, 2026EPS Estimate
1.31Next Dividend Ex-DateN/A
Dividend Yield0.12%
Share Statistics
EPS (TTM)0.95
Shares Outstanding1,620,907,700
10 Day Avg. Volume177,351
30 Day Avg. Volume208,504
Financial Highlights & Ratios
PEG Ratio-38.08
Price to Book (P/B)1.88
Price to Sales (P/S)2.66
P/FCF Ratio23.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹435.00Price Target Upside19.44% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)9.15
Revenue Forecast (FY)₹202.32B
Bulls Say, Bears Say
Bulls Say
Diversified Biopharma ModelVertical integration across R&D, large-scale biologics, small-molecule manufacturing and CDMO creates multiple durable revenue streams. Scale and breadth reduce dependence on any single product, support margin resilience, and raise barriers to entry for competitors over the next several quarters.
Consistent Revenue GrowthSustained ~14% revenue growth signals expanding commercial traction and product adoption across markets. When paired with recurring biosimilar and CDMO contracts, this growth provides a durable base to fund R&D and commercial investments, supporting medium-term strategic priorities.
Healthy Cash Generation & Balance SheetPositive operating and free cash flow plus a strong equity ratio provide financial flexibility to fund capex, clinical programs and partnerships without heavy refinancing. Robust cash conversion supports sustainable investment in pipeline and capacity over 2-6 months.
Bears Say
Rising Total Debt RiskA rising absolute debt level, although currently manageable, reduces financial optionality and increases interest exposure if macro rates rise. Continued debt accumulation could pressure free cash flow allocation and constrain strategic spending if revenue growth or margins weaken.
Declining EBIT MarginA shrinking EBIT margin suggests operational cost pressures or mix shifts that could compress core profitability. If margin erosion continues, it will limit the company’s ability to reinvest in R&D and capacity while maintaining returns, weakening long-term earnings quality.
EPS ContractionMaterial negative EPS growth despite revenue gains indicates profit per share weakness, possibly from non-operating items, dilution, or margin pressure. Persisting EPS contraction undermines shareholder returns and raises questions on near-term earnings sustainability.
Biocon Limited News
BIOCON FAQ
What was Biocon Limited’s price range in the past 12 months?
Biocon Limited lowest stock price was ₹303.85 and its highest was ₹424.95 in the past 12 months.
What is Biocon Limited’s market cap?
Biocon Limited’s market cap is ₹566.77B.
When is Biocon Limited’s upcoming earnings report date?
Biocon Limited’s upcoming earnings report date is May 14, 2026 which is in 35 days.
How were Biocon Limited’s earnings last quarter?
Biocon Limited released its earnings results on Feb 12, 2026. The company reported ₹0.947 earnings per share for the quarter, missing the consensus estimate of ₹1.166 by -₹0.219.
Is Biocon Limited overvalued?
According to Wall Street analysts Biocon Limited’s price is currently Undervalued.
Does Biocon Limited pay dividends?
Biocon Limited pays a Annually dividend of ₹0.5 which represents an annual dividend yield of 0.12%. See more information on Biocon Limited dividends here
What is Biocon Limited’s EPS estimate?
Biocon Limited’s EPS estimate is 1.31.
How many shares outstanding does Biocon Limited have?
Biocon Limited has 1,620,907,700 shares outstanding.
What happened to Biocon Limited’s price movement after its last earnings report?
Biocon Limited reported an EPS of ₹0.947 in its last earnings report, missing expectations of ₹1.166. Following the earnings report the stock price went down -0.146%.
Which hedge fund is a major shareholder of Biocon Limited?
Currently, no hedge funds are holding shares in IN:BIOCON
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Biocon Limited
Biocon Limited, a biopharmaceutical company, manufactures pharmaceuticals, and medicinal chemical and botanical products. The company operates through Generics, Novel Biologics, Biosimilars, and Research Services segments. It focuses in the areas of diabetes, oncology, immunology, ophthalmology, and bone health diseases. In addition, It is involved in the integrated discovery, development, and manufacturing services for small and large molecules. The company serves customers in approximately 120 countries. Biocon Limited was founded in 1978 and is headquartered in Bengaluru, India.
BIOCON Stock 12 Month Forecast
Average Price Target
₹435.00
▲(19.44% Upside)
Technical Analysis
Blue Jet Healthcare Limited
―
Concord Biotech Ltd.
―
Jubilant Ingrevia Ltd.
―
Piramal Pharma Limited
―
Syngene International Ltd.
―